Scilex Holding's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Scilex Holding (SCLX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Scilex Holding vs Its Competitors
- TTM: Trailing 12-month revenue of 32M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-3.3% annualized vs trailing 12 months).
- Scale: Scilex Holding ranks #117 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
- Peer revenue share: Scilex Holding accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SCLX Sales vs. its Competitors, Q2 2026
Scilex Holding generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs -22.8% for Scilex Holding. Scilex Holding's share of combined industry revenue moved from 0.03% to 0.02%, a loss of 0.01 percentage points.
Scilex Holding's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Scilex Holding Company | No | No | No | - |
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 50.00 % (4 of 8) | 37.50 % (3 of 8) | 28.60 % (2 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SCLX Stock Performance relative to its Competitors
SCLX Stock Performance relative to High-Confidence Competitors
SCLX Stock Performance relative to Similar-Size Competitors
SCLX Stock Performance relative to Similar Growth & Profitability Competitors
Scilex Holding's Comment on Competition and Industry Peers
Scilex Holding's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Lidoderm | Named by the company | 85% |
| Sanofi | Named by the company | 85% |
| Mylan | Named by the company | 85% |
| Genzyme | Named by the company | 85% |
| Teva | Named by the company | 85% |
| Par Pharmaceutical, Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Scilex Holding's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.